Feb

2012

Ember Therapeutics, Inc.: Series A $34.1M

Posted in I - Series A, Q - 4Q11, R - NORTH EAST, X - Diabetes, X - Metabolism, X - Obesity, X - Therapeutic Platform, XX - MA

Ember Therapeutics (Boston, MA) a preclinical-stage pharmaceutical company focused on diabetes, obesity and metabolic diseases closed a $34.1M Series A financing. Participants include Third Rock Ventures.

Jan

2012

Aviir, Inc.: Series E $10M

Posted in I - Series E, Q - 4Q11, R - WEST, X - Cardiology, X - Device (Diagnostic), X - Metabolism, XX - CA

Aviir (Irvine, CA) a commercial-stage diagnostic company focused on pharmacogenomic and genetic tests for risk assessment and therapeutic monitoring of cardiovascular disease and related metabolic disorders, closed a $10M Series E financing. Participants include Merck Global Health Innovation, Bay City Capital, Aberdare Ventures and New Leaf Venture Partners.

Jan

2012

Agios Pharmaceuticals, Inc.: Series C $78M

Posted in I - Series C, Q - 4Q11, R - NORTH EAST, X - Metabolism, X - Oncology, XX - MA

Agios Pharmaceuticals (Cambridge, MA) a clinical-stage biopharmaceutical company focused on cancer metabolism, closed a $78M Series C financing. Participants have included Celgene, ARCH Venture Partners, Flagship Ventures and Third Rock Ventures.

Aug

2011

Ultragenyx Pharmaceutical, Inc.: Series A $45M

Posted in I - Series A, Q - 2Q11, R - WEST, X - Metabolism, XX - CA

Ultragenyx Pharmaceutical (Novato, CA) a clinical-stage pharmaceutical company focused on inclusion body myopathy and other rare metabolic disease,vclosed a $45M Series A financing. Participants include TPG Biotech, Fidelity Biosciences, HealthCap and Pappas Ventures.

May

2011

Nimbus Discovery, LLC: Series A $1.5M

Posted in I - Series A, Q - 1Q11, R - NORTH EAST, X - Computational Discovery, X - Metabolism, X - Oncology, XX - MA

Nimbus Discovery (Cambridge, MA) a development-stage biopharmaceutical focused on computational technologies to identify lead candidates for diffuse B-cell lymphoma and metabolic disease, closed a $1.5M Series A bringing the total financing to $5M. Participants include the Bill and Melinda Gates Foundation and Atlas Venture.

Mar

2011

Synageva BioPharma Corp.: Series C $25M

Posted in I - Series C, Q - 1Q11, R - NORTH EAST, X - Lysosomal Storage, X - Metabolism, XX - MA

Synageva BioPharma (Lexington, MA) a clinical-stage biopharma focused on rare diseases and orphan therapeutics for the treatment of lysosomal storage disease and metabolic disorders, closed a $25M Series C financing. Participants have included New Leaf Venture Partners, Hunt BioVentures, Yasuda Enterprise Development, Baker Brothers Investments, Tullis Dickerson and Four Partners.

Jan

2011

Acylin Therapeutics, Inc.: Series A $4.4M

Posted in I - Series A, Q - 4Q10, R - NORTH WEST, X - CNS, X - Metabolism, X - Oncology, XX - WA

Acylin Therapeutics (Seattle, WA) a development-stage biopharma company focused on inhibiting histone acetyltransferase in cancer, metabolic disease, and neurodegeneration indications, closed a $4.4M Series F financing. Participants include Alexandria Real Estate Equities, Amgen Ventures, ARCH Venture Partners, OVP Venture Partners, PPD and Washington Research Foundation Capital.

Nov

2010

aTyr Pharma, Inc.: Series C $23M

Posted in I - Series C, Q - 4Q10, R - WEST, X - Hematology, X - Immunology, X - Metabolism, XX - CA

aTyr Pharma (San Diego, CA) a preclinical-stage biopharmaceutical company focused on immune, metabolic and hematologic indications, closed a $23M Series C financing. Participants include Domain Associates, Alta Partners, Cardinal Partners and Polaris Ventures.

Oct

2010

NewBridge Pharmaceuticals, Inc.: Series B $12M

Posted in I - Series B, Q - 3Q10, R - WEST, X - GI, X - Metabolism, X - Oncology, XX - CA

NewBridge Pharmaceuticals (San Francisco, CA) a commercial-stage biopharmaceutical company focused on oncology, GI and metabolic disorders, closed a $12M Series B financing. Participants include Kuwait Life Sciences Company and Burrill & Co.

Aug

2010

Poxel, SA: Series A $20.3M

Posted in I - Series A, Q - 3Q10, R - INTERNATIONAL, X - Diabetes, X - Metabolism

Poxel (France) a clinical-stage small molecule company focused on Type-2 diabetes and metabolic disease, closed a $20.3M Series A financing. Participants include Edmond de Rothschild Investment Partners, InnoBio Ventures and Crédit Agricole Private Equity.

Jun

2010

Aquinox Pharmaceuticals, Inc.: Series B $25M

Posted in I - Series B, Q - 2Q10, R - INTERNATIONAL, X - Metabolism, X - Oncology

Aquinox Pharmaceuticals (Canada) a preclinical-stage small-molecule drug company focused on cancer, immune disorders and metabolic disease, closed a $25M Series B financing. Participants include Ventures West Capital, Johnson & Johnson Development Corp., Baker Brothers Investments, BC Advantage Funds and Pfizer Venture Investments.

Apr

2010

Catabasis Pharmaceuticals, Inc.: Series A $39.6M

Posted in I - Series A, Q - 2Q10, R - NORTH EAST, X - Inflammation, X - Metabolism, XX - MA

Catabasis Pharmaceuticals (Cambridge, MA) a preclinical-stage company focused on lipid mediators for the treatment of inflammatory and metabolic diseases, closed a $39.6M Series A financing. Participants include SV Life Sciences, Clarus Ventures, MedImmune Ventures and Advanced Technology Ventures.

Mar

2010

NGM Biopharmaceuticals, Inc.: Series B $51M

Posted in I - Series B, Q - 1Q10, R - WEST, X - Diabetes, X - Metabolism, X - Obesity, XX - CA

NGM Biopharmaceuticals (San Francisco, CA) a preclinical-stage biopharmaceutical company focused on diabetes, obesity and muscle wasting, closed a $51M Series B financing. Participants include The Column Group, Tichenor Ventures, Prospect Venture Partners and Rho Ventures.

« Previous Entries

to top of page...